PURE Bioscience (OTCMKTS:PURE) Sees Large Growth in Short Interest

PURE Bioscience (OTCMKTS:PURE) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totaling 11,031 shares, an increase of 191.0% from the June 15th total of 3,791 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 30,287 shares, the days-to-cover ratio is currently 0.4 days.

PURE Bioscience Price Performance

Shares of PURE Bioscience stock traded up $0.00 during trading on Monday, hitting $0.07. 1,980 shares of the company’s stock traded hands, compared to its average volume of 32,994. PURE Bioscience has a 1 year low of $0.04 and a 1 year high of $0.14. The business has a 50-day simple moving average of $0.07 and a 200-day simple moving average of $0.06. The stock has a market capitalization of $8.58 million, a P/E ratio of -2.20 and a beta of 0.22.

PURE Bioscience (OTCMKTS:PURE) last issued its earnings results on Monday, June 15th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.51 million for the quarter.

About PURE Bioscience

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.